- Home
- NBTX vs MGIC Comparison
NBTX vs MGIC Comparison
Compare NBTX & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBTX | MGIC |
|---|---|---|
| Founded | 2003 | 1983 |
| Country | France | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2020 | 1991 |
Fundamental Metrics
Financial Performance| Metric | NBTX | MGIC |
|---|---|---|
| Price | $24.85 | $18.86 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $26.00 | $18.00 |
| AVG Volume (30 Days) | 22.3K | ★ 28.8K |
| Earning Date | 04-01-2026 | 03-10-2026 |
| Dividend Yield | N/A | ★ 3.20% |
| EPS Growth | N/A | ★ 16.15 |
| EPS | N/A | ★ 0.81 |
| Revenue | $11,930,711.00 | ★ $603,216,000.00 |
| Revenue This Year | N/A | $12.87 |
| Revenue Next Year | $145.24 | $6.23 |
| P/E Ratio | ★ N/A | $23.27 |
| Revenue Growth | N/A | ★ 12.65 |
| 52 Week Low | $2.95 | $11.65 |
| 52 Week High | $30.35 | $28.00 |
Technical Indicators
Market Signals| Indicator | NBTX | MGIC |
|---|---|---|
| Relative Strength Index (RSI) | 60.40 | 27.25 |
| Support Level | $22.76 | $18.62 |
| Resistance Level | $25.55 | $23.40 |
| Average True Range (ATR) | 1.13 | 0.75 |
| MACD | 0.40 | -0.74 |
| Stochastic Oscillator | 72.91 | 1.47 |
Price Performance
Historical ComparisonAbout NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.